This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
8/1/2024
Operator
Conference Operator
during the question and answer session. Please note today's call will be recorded and I will be standing by should you need any assistance. It is now my pleasure to turn the conference over to Vice President of Investor Relations, Todd Tushla. Please go ahead.
Todd Tushla
Vice President of Investor Relations
Thank you, Chloe. Welcome to Nurocrine Biosciences second quarter 2024 earnings call. With me are Kevin Gorman, our current Chief Executive Officer. Matt Abernathy, Chief Financial Officer.
Todd Tushla
Vice President of Investor Relations
Ivory Roberts, Chief Medical Officer. Eric Berger, Chief Financial Officer. Eric Berger, Chief Financial Officer.
You're reading a preview of the NBIX Q2 2024 earnings call.
Free account.
Disclaimer